VPVeronica Polelli

Veronica Polelli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Veronica Polelli has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The clinical impact of bronchoscopy: balancing microbiology and inflammatory endotyping

    by Alessandro De Angelis, Edoardo Simonetta, Paola Scarano, Angela Tramontano, Mattia Nigro, Martina Lo Casto, Manuel Mancuso, Veronica Polelli, Salvatore Battaglia, Claudia Crimi, et al.

    Extract We would like to thank L. Nguyen-Ho and Q-K. Tran-Le for their insightful comments on our study regarding the clinical impact of bronchoscopy in bronchiectasis management [1]. Their highlights regarding the potential role of bronchial lavage (BL) in inflammatory endotyping beyond microbiology are both timely and highly relevant. Shareable abstract Think bronchoscopy is just for samples? Think again. It impacts clinical management in >50% of bronchiectasis cases with a high safety profile: moving from expert opinion to data-driven care. https://bit.ly/3NYVAM3

  • Open Access

    Clinical heterogeneity of bronchiectasis exacerbations: a multicentre real-world study

    by Angela Tramontano, Mattia Nigro, Edoardo Simonetta, Paola Scarano, Alessandro De Angelis, Veronica Polelli, Emanuele Toni, Giacomo Barzaghi, Salvatore Battaglia, Martina Bonifazi, et al.

    Background and aim: Exacerbations are critical events in the natural history of bronchiectasis. While an international definition has been proposed for clinical trials by an EMBARC/BRR task force, the clinical presentation of exacerbations varies considerably among patients. The aim of our study was to assess the clinical heterogeneity of signs and symptoms of bronchiectasis exacerbations in a real-world setting. Methods: This was a multicentre cross-sectional study involving nine bronchiectasis centres in Italy. Consecutive adults with bronchiectasis reported symptoms during stable-state and during typical exacerbations over the past 2 years. Symptom frequency, their impact on daily life, and concordance with the 2017 EMBARC/BRR definition were assessed overall and by comorbidity/infection subgroups. Results: We enrolled 367 patients (79% female; median age 65 years). During exacerbations, cough (87%), increased sputum volume (81%), and purulence (77%) predominated and clustered with fatigue (72%) and exertional dyspnoea (64%). Patients ranked cough and sputum changes as highest impact. Overall, 85% of typical exacerbations met EMBARC/BRR criteria; exacerbation events that were not concordant with EMBARC/BRR criteria were more frequent in patients with NTM-PD (p=0.004). Patients with asthma/COPD as comorbidity reported more dyspnoea and wheezing, patients with chronic P. aeruginosa infection more frequently reported haemoptysis and nocturnal dyspnoea. Conclusions: Exacerbations present with distinct symptom patterns across subgroups, and about one in seven typical patient reported events do not meet consensus criteria, underscoring the need for more sensitive patient-centred definitions.

  • Open Access

    Bronchiectasis in Italy: an analysis of the EMBARC registry

    by Stefano Aliberti, Andrea Gramegna, Edoardo Simonetta, Alessandro De Angelis, Mattia Nigro, Anna Stainer, Francesco Amati, Salvatore Battaglia, Giovanni Sotgiu, Federico Dente, et al.

    Background: Bronchiectasis is a complex disease with geographical variability in its presentation and management. Despite the growing contribution of international registries, real-world data on the Italian bronchiectasis population remain limited. The objective of the present study was to describe the demographic, clinical, microbiological, functional and treatment characteristics of Italian patients with bronchiectasis and to compare them with those of patients from other Southern European countries. Methods: This was a secondary analysis of adults from 18 Italian centres included in the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) registry, with comparisons made to patients in Spain, Greece, Portugal, Turkey, Israel and Malta (Southern European countries). Demographics, comorbidities, exacerbation history, spirometry, microbiology and treatment patterns were evaluated. Results: Among 1657 Italian patients, the majority were female (70.5%) with a median age of 65 years, with high rates of idiopathic bronchiectasis (55.4%) and preserved lung function. Compared with other Southern European countries (n=2638), Italian patients had lower disease severity (median Bronchiectasis Severity Index: 6 versus 7; pPseudomonas aeruginosa , and lower prevalence of daily sputum production and purulence, despite identical quality of life (median Quality of Life Questionnaire-Bronchiectasis Respiratory Symptom Score: 70.4 in both groups). Treatment patterns differed, with lower use of inhaled antibiotics (1.1% versus 13.1%) and macrolides (6.0% versus 14.3%), but more widespread use of airway clearance (48.4% versus 35.9%) among patients from Italy versus other Southern European countries. Conclusions: These findings may reflect earlier referral, diagnostic preferences or structural differences in care delivery in Italy compared with other Southern European countries. This work lays the foundation for tailored national strategies and future longitudinal studies. The largest bronchiectasis cohort ever studied in Italy reveals unique clinical traits and highlights key differences from other Southern European countries, and provides real-world data to shape better care models and guide future research.

  • Open Access

    Clinical profile and in-hospital outcomes of patients hospitalised for bronchiectasis exacerbation

    by Francesco Bindo, Edoardo Simonetta, Andrea Gramegna, Paola Faverio, Paola Scarano, Veronica Polelli, Anna Stainer, Francesco Amati, Mattia Nigro, Angela Tramontano, et al.

    Exacerbations play a pivotal role in the natural history of bronchiectasis, driving symptom worsening, accelerating lung function decline and increasing mortality risk [1, 2]. Exacerbations requiring hospitalisation have particularly severe consequences – not only for individual patients but also for healthcare systems, due to prolonged admissions, the need for intensive care, and post-discharge complications [3]. These events are frequently associated with complex clinical presentations involving respiratory failure, cardiovascular instability and the need for ventilatory support [1].

  • Open Access

    S taphylococcus aureus in bronchiectasis: epidemiology, clinical impact and challenges in management

    by Alessandro De Angelis, Martina Lo Casto, Vincenzo Alberto Artuso, Francesco Del Bello, Angela Tramontano, Mattia Nigro, Edoardo Simonetta, Paola Scarano, Veronica Polelli, Stefano Aliberti

    Bronchiectasis is a chronic respiratory disease characterised by permanent bronchial dilation, productive cough and recurrent exacerbations. Staphylococcus aureus (including methicillin-resistant strains (methicillin-resistant S. aureus (MRSA)) is increasingly recognised as a relevant pathogen in bronchiectasis, although its role remains less well defined than that of Pseudomonas aeruginosa or Haemophilus influenzae . This narrative review examines the epidemiological, pathophysiological, clinical and therapeutic implications of S. aureus infection in adults with bronchiectasis, drawing comparisons with other disease models. Epidemiological data reveal a lower prevalence of S. aureus in bronchiectasis compared to other pathogens, with significant regional variation. Its clinical impact is debated, with some studies associating chronic S. aureus infection with more severe disease, while others consider it a marker of severity rather than a direct driver of progression. Unlike P. aeruginosa , current guidelines do not recommend specific eradication or long-term suppressive strategies for S. aureus . British guidelines suggest MRSA eradication may be considered in cases of clinical deterioration, although no standardised protocol exists. Exacerbations are managed with a 14-day course of targeted antibiotics. Preventive strategies, including decolonisation and vaccine development, are under investigation or adapted from other clinical contexts. While no vaccine is currently available, monoclonal antibodies targeting S. aureus toxins have shown promise in early trials. Further research is needed to clarify the pathogen's role in disease progression and the efficacy of targeted therapies. This review also outlines clinical practice points and research priorities to support evidence-based management.

  • Open Access

    Home-based rehabilitation in interstitial lung disease: picturing the present and drawing the future through a systematic review of the literature

    by Gabriele Bongiovanni, Veronica Polelli, Anna Stainer, Massimiliano Russo, Roberto Gatti, Stefano Aliberti, Francesco Amati

    Background: Rehabilitation represents a key nonpharmacological treatment for patients with interstitial lung diseases (ILDs). As a consequence of improvement in technologies and social distancing in the SARS-CoV-2 era, a growing body of evidence demonstrated the effectiveness of tele-rehabilitation programmes for chronic respiratory diseases. Methods: We conducted a systematic review to identify randomised controlled trials (RCTs) on tele-rehabilitation in ILD and extended the search to ongoing trials. Results: Throughout our research, we identified four RCTs describing home rehabilitation in ILD. All RCTs were heterogenous small trials. Thus, a meta-analysis could not be performed, and data were reported in a descriptive way. The primary outcomes of the RCTs analysed included both physical and functional measures. We also identified through ClinicalTrials.gov four ongoing clinical trials investigating pulmonary rehabilitation in ILD with a considerable degree of heterogeneity regarding the populations included. In our systematic review, we also highlighted the key pillars for future trials in the field. Conclusion: Potential treatment trajectories on outcomes of ILD patients related to the implementation of tele-rehabilitation are also discussed.

  • Open Access

    How bronchoscopy can impact bronchiectasis management: a prospective, observational study

    by Alessandro De Angelis, Edoardo Simonetta, Paola Scarano, Angela Tramontano, Mattia Nigro, Martina Lo Casto, Manuel Mancuso, Veronica Polelli, Salvatore Battaglia, Claudia Crimi, et al.

    Bronchiectasis is a chronic respiratory condition characterised by irreversible bronchial dilatation, persistent respiratory symptoms and recurrent exacerbations [1]. Despite significant progress in understanding its pathophysiology, many diagnostic and therapeutic decisions remain based on expert opinion [2, 3]. In particular, the role of bronchoscopy remains debated. According to current guidelines, bronchoscopy should be considered in patients with nonproductive cough and signs of infection on computed tomography (CT), or when obstructive causes or nontuberculous mycobacterial pulmonary disease (NTM-PD) are suspected [2, 3].


  • Open Access

    The role of screening for connective tissue diseases in bronchiectasis: an observational study

    by Anna Stainer, Mattia Nigro, Andrea Gramegna, Edoardo Simonetta, Francesco Amati, Veronica Polelli, Angela Tramontano, Sofia Misuraca, Letizia Corinna Morlacchi, Francesco Blasi, et al.

    Bronchiectasis is a chronic respiratory disease characterised by permanent bronchial dilatation associated with chronic productive cough and recurrent respiratory infections [1]. The European Respiratory Society (ERS) guidelines recommend etiological screening at the time of bronchiectasis diagnosis to identify treatable causes or those that may influence disease management [2]. Data from EMBARC, the European bronchiectasis registry, suggest an association between bronchiectasis and rheumatoid arthritis (RA) in up to 2.7% of cases, while other connective tissue diseases (CTDs) are present in up to 2.1% of cases [3].


  • Open Access

    Prevalence and types of treatable traits in bronchiectasis: a multicentre, cross-sectional study

    by Marianna Cicchetti, Alessandro De Angelis, Edoardo Simonetta, Andrea Gramegna, Paola Faverio, Martina Contarini, Francesco Amati, Vincenzo Alberto Artuso, Angela Tramontano, Mattia Nigro, et al.

    Bronchiectasis is a heterogeneous chronic respiratory disease characterised by permanent bronchial dilation, daily productive cough and frequent exacerbations [1]. In recent years, the understanding of bronchiectasis has evolved beyond the paradigm of recurrent infections and structural lung damage. Systemic inflammation and coexisting comorbidities are now recognised as integral components of disease pathophysiology [2–4]. Moreover, patients increasingly emphasise the need for personalised and flexible management strategies, pointing out the limitations of a one-size-fits-all approach [5].


  • Open Access

    Haemophilus influenzae in bronchiectasis

    by Alessandro De Angelis, Martina Marchello, Angela Tramontano, Marianna Cicchetti, Mattia Nigro, Edoardo Simonetta, Paola Scarano, Veronica Polelli, Vincenzo Alberto Artuso, Stefano Aliberti

    Bronchiectasis is a chronic respiratory disease characterised by irreversible bronchial dilation, persistent productive cough and alternating periods of clinical stability and exacerbations. The distorted airways impair mucus clearance, making them susceptible to recurrent infections and chronic inflammation. Haemophilus influenzae is a common pathogen in bronchiectasis according to international registries. It employs several virulence mechanisms, including adhesion, intracellular invasion/survival, biofilm formation and evasion of antibiotic treatments, to establish infection. These mechanisms allow H. influenzae to persist in the respiratory tract and evade host immune defences. Although its role is well-documented in other airway diseases, the impact of H. influenzae in bronchiectasis remains incompletely understood. International guidelines do not recommend eradication therapy for H. influenzae upon first isolation, while this intervention is advised for Pseudomonas aeruginosa in such cases. Long-term immunomodulatory treatment with macrolides is an option for patients with bronchiectasis with chronic H. influenzae infection and frequent exacerbations, though it carries the risk of promoting antibiotic resistance and a Pseudomonas-enriched airway microbiome. Studies indicate significant negative interactions between P. aeruginosa and H. influenzae, suggesting a competitive relationship that can influence microbiome dynamics and potentially affect clinical outcomes. Currently, there is insufficient evidence to support vaccination against nontypeable H. influenzae in chronic airways disease. Despite its frequent detection in respiratory samples, the precise role of H. influenzae in bronchiectasis-related morbidity and disease progression is not fully understood and warrants further investigation. This review examines the impact of H. influenzae on bronchiectasis pathophysiology and progression, comparing its role in other chronic respiratory diseases.